Get the Stockscreener App
0.8611
2.35%
-0.0285
Atossa Therapeutics Inc stock is traded at $0.8611, with a volume of 174.46K.
It is down -2.35% in the last 24 hours and down -13.99% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$0.8896
Open:
$0.9
24h Volume:
174.46K
Relative Volume:
0.21
Market Cap:
$111.23M
Revenue:
-
Net Income/Loss:
$-26.91M
P/E Ratio:
-3.9141
EPS:
-0.22
Net Cash Flow:
$-19.57M
1W Performance:
-7.90%
1M Performance:
-13.99%
6M Performance:
+1.55%
1Y Performance:
-38.82%
1-Day Range:
$0.861
$0.907
1-Week Range:
$0.8596
$0.9579
52-Week Range:
$0.5526
$1.66
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Compare ATOS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATOS
Atossa Therapeutics Inc
|
0.8611 | 114.91M | 0 | -26.91M | -19.57M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.19 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
633.67 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.81 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
821.48 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.32 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Is Atossa Therapeutics Inc. reversing from oversold territoryLong Setup & Entry Point Confirmation Signals - newser.com
Does Atossa Therapeutics Inc. fit your quant trading modelMarket Performance Summary & Long-Term Capital Growth Strategies - newser.com
Is a relief rally coming for Atossa Therapeutics Inc. holdersJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Atossa Therapeutics Inc. stock trend outlook and recovery pathMarket Activity Recap & Scalable Portfolio Growth Ideas - newser.com
What earnings revisions data tells us about Atossa Therapeutics Inc.Analyst Downgrade & Community Verified Watchlist Alerts - newser.com
Why Atossa Therapeutics Inc. stock is seen as undervaluedJuly 2025 Retail & Free AI Powered Buy and Sell Recommendations - newser.com
Candlestick signals on Atossa Therapeutics Inc. stock todayEarnings Miss & Low Drawdown Momentum Trade Ideas - newser.com
How Atossa Therapeutics Inc. stock trades before earningsJuly 2025 Setups & High Conviction Investment Ideas - newser.com
How rising interest rates impact Atossa Therapeutics Inc. stockJuly 2025 Big Picture & Risk Managed Investment Entry Signals - newser.com
How Atossa Therapeutics Inc. (YAG2) stock trades after earningsDividend Hike & Accurate Entry/Exit Alerts - newser.com
Is Atossa Therapeutics Inc. stock a smart buy before Fed meetingGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Is Atossa Therapeutics Inc. stock attractive for income investors2025 Trade Ideas & Verified Short-Term Plans - newser.com
Will Atossa Therapeutics Inc. stock split again soonWeekly Profit Recap & Pattern Based Trade Signal System - newser.com
What moving averages say about Atossa Therapeutics Inc.Quarterly Profit Review & Weekly Breakout Stock Alerts - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock hit analyst forecastsPortfolio Return Report & Weekly Market Pulse Updates - newser.com
Visual analytics tools that track Atossa Therapeutics Inc. performance2025 EndofYear Setup & Free High Return Stock Watch Alerts - newser.com
Atossa Genetics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Atossa Genetics Inc. (NASDAQ:ATOS) Sees Large Drop in Short Interest - MarketBeat
Applying big data sentiment scoring on Atossa Therapeutics Inc.Portfolio Update Summary & Low Drawdown Trading Strategies - newser.com
Can Atossa Therapeutics Inc. (YAG2) stock reach $200 price target2025 Market Sentiment & Reliable Intraday Trade Alerts - newser.com
Is Atossa Therapeutics Inc. (YAG2) stock inflation resilientJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - newser.com
NioCorp and Atossa Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Amarillo Globe-News
Published on: 2025-10-31 05:58:12 - newser.com
What hedge fund moves indicate for Atossa Therapeutics Inc. (YAG2) stockLong Setup & Risk Adjusted Swing Trade Ideas - newser.com
Can Atossa Therapeutics Inc. stock sustain market leadershipJuly 2025 Recap & Capital Efficiency Focused Ideas - newser.com
When is the best time to exit Atossa Therapeutics Inc.2025 Performance Recap & Weekly High Momentum Picks - newser.com
Atossa Therapeutics Inc. stock outlook for YEARJuly 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Will Atossa Therapeutics Inc. stock benefit from commodity pricesMarket Growth Report & Stepwise Trade Signal Implementation - newser.com
Detecting price anomalies in Atossa Therapeutics Inc. with AIOptions Play & Verified Momentum Stock Watchlist - newser.com
How cyclical is Atossa Therapeutics Inc. (YAG2) stock compared to rivalsJuly 2025 Drop Watch & Community Shared Stock Ideas - newser.com
How high can Atossa Therapeutics Inc. stock goCPI Data & Safe Capital Growth Tips - newser.com
Published on: 2025-10-31 00:04:50 - newser.com
Will Atossa Therapeutics Inc. (YAG2) stock announce a stock splitWeekly Risk Report & Free Real-Time Volume Trigger Notifications - newser.com
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):